What’s the Analyst Recommendation for Soleno Therapeutics Inc. (SLNO)?

Guggenheim announced it was Initiated coverage of Soleno Therapeutics Inc. in a research note on September 29, 2020. Craig Hallum rated the stock as a Buy in a research noted published on January 10, 2020. Oppenheimer rated the stock as an Outperform in a research note published on December 23, 2019.

Sinclair Andrew, the Director of Soleno Therapeutics Inc., bought 3.33 million shares at the valuation of $1.65 during an exchange that occurred on Jun 26, which implies that Sinclair Andrew is holding 10,302,602 shares at the estimation of $5,499,995.

In another transaction, on Jun 26, 10% Owner of Soleno Therapeutics Inc., Abingworth LLP, bought 3.33 million shares at the price of $1.65. After this activity, Abingworth LLP now keeps 10,302,602 shares of Soleno Therapeutics Inc., esteemed at $5,499,995.

SLNO Recent Trade

The share price of SLNO ascended by $0.44 during the exchanging session on 09/30/20 to exchange at $2.51. Soleno Therapeutics Inc. stock has an exchanging volume of 5.54 million shares, which is high, contrasted with its 3-months average volume of 653.40K shares. Its market capitalization has now reached to $195.50M.

SLNO Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, SLNO price has rose by 39.06%. In the course of past three months sees the stock go up around 21.84%, while it has gain 1.62% over the past six months and -14.63% since the start of the year.

SLNO Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), Soleno Therapeutics Inc. posted -$0.16 earnings per share (EPS) which was above the consensus estimate of -$0.2 by $0.04, which represents to an expansion by 20.00%.

SLNO Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Soleno Therapeutics Inc. has seen its stock exchanging -16.33% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +52.12% above its three-month low. A more extensive look sees SLNO exchanging -42.82% beneath its 52-week high and 112.71% above from its 52-week low price.

SLNO Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 15.52%, while it has a month to month instability of 11.07%. The company has an ATR (Average True Range) of 0.23 and a beta factor of 0.61.

Leave a Comment